- Home
- MNPR vs GMRE Comparison
MNPR vs GMRE Comparison
Compare MNPR & GMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- GMRE
- Stock Information
- Founded
- MNPR 2014
- GMRE 2011
- Country
- MNPR United States
- GMRE United States
- Employees
- MNPR N/A
- GMRE N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- GMRE Real Estate Investment Trusts
- Sector
- MNPR Health Care
- GMRE Real Estate
- Exchange
- MNPR Nasdaq
- GMRE Nasdaq
- Market Cap
- MNPR 390.5M
- GMRE 428.4M
- IPO Year
- MNPR 2019
- GMRE N/A
- Fundamental
- Price
- MNPR $86.16
- GMRE $30.70
- Analyst Decision
- MNPR Strong Buy
- GMRE Buy
- Analyst Count
- MNPR 12
- GMRE 2
- Target Price
- MNPR $96.64
- GMRE $42.50
- AVG Volume (30 Days)
- MNPR 97.3K
- GMRE 204.0K
- Earning Date
- MNPR 11-10-2025
- GMRE 11-04-2025
- Dividend Yield
- MNPR N/A
- GMRE 9.77%
- EPS Growth
- MNPR N/A
- GMRE N/A
- EPS
- MNPR N/A
- GMRE 0.34
- Revenue
- MNPR N/A
- GMRE $141,896,000.00
- Revenue This Year
- MNPR N/A
- GMRE $8.69
- Revenue Next Year
- MNPR N/A
- GMRE $5.10
- P/E Ratio
- MNPR N/A
- GMRE $91.50
- Revenue Growth
- MNPR N/A
- GMRE 2.95
- 52 Week Low
- MNPR $12.55
- GMRE $30.09
- 52 Week High
- MNPR $105.00
- GMRE $47.00
- Technical
- Relative Strength Index (RSI)
- MNPR 57.75
- GMRE 60.15
- Support Level
- MNPR $77.00
- GMRE $30.73
- Resistance Level
- MNPR $89.32
- GMRE $31.46
- Average True Range (ATR)
- MNPR 7.00
- GMRE 0.76
- MACD
- MNPR -1.45
- GMRE -0.88
- Stochastic Oscillator
- MNPR 44.25
- GMRE 9.62
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.